OxSonics Therapeutics with new Chief Executive Officer
At the beginning of november, OxSonics Therapeutics has appointed Jérôme Marzinski as its Chief Executive Officer.
OxSonics Therapeutics is a clinical-stage therapeutics company, transforming cancer treatment by harnessing its proprietary technology platform SonoTran® to enhance the delivery and improve the efficacy of oncology drugs. Its based in Oxford, UK.
Marzinski having held a variety of senior roles over a more than 25 year career, with significant experience in scaling venture capital and private equity-funded businesses in the sector, having completed 15 M&A transactions and raised over 50m of growth capital.
The finance expert is an independent Board member of Cimon Medical, where he was also the Interim Chief Executive Officer from January 2022. Prior to this, he spent three years as Chief Executive Officer at Visiometrics, an ophthalmic diagnostic company, that has developed and commercialized a breakthrough diagnostic for vision impairment and cataract detection. He also spent six years in senior positions at ev3, which was sold to Covidien in 2012, and served as Chief Operating Officer of Vexim.
He is an independent Board member and strategic advisor to life sciences start-up Aniling and owns MedCape Advisors, a management consulting agency for life sciences companies, providing advice on go-to-market strategy as well as international expansion.
Marzinski studied corporate finance and accounting at the University of Lille (MA) and completed the TRIUM Global Executive MBA in 2012.
Astoriom
